Wedbush lowers Larimar Therapeutics stock price target on funding
Wedbush cut its price target on Larimar Therapeutics (LRMR) to $9 from $11, citing funding concerns, while maintaining an Outperform rating. The stock is up 19% in the past week. The company has $129M in cash, enough to last until late Q2 2027, but faces high cash burn. Wedbush expects BLA acceptance in January and potential fundraising in Q1 2027.
How this was made
The 30-second read
Why it matters
Analyst downgrade reflects concerns over cash burn and regulatory timing, but the company retains a strong balance sheet.
Market read
Target reduction may trigger short‑term sell pressure in LRMR, while the broader biotech sector remains sensitive to regulatory milestones.
What to watch
Potential Priority Review Voucher and cash runway may support upside despite target reduction.
Background
Larimar Therapeutics reported $129 M cash, negative free cash flow, and a pending BLA submission for its drug nomlabofusp.
Ticker impact
Wedbush lowered its price target for Larimar Therapeutics to $9 from $11, maintaining an Outperform rating.
likely downward pressure as investors price in the reduced target.
Target reduction is a fresh analyst action on a micro‑cap biotech; traders may adjust positions promptly.
Market effects
May dampen sentiment toward small‑cap biotech sector as analysts tighten expectations.
Limited to US‑listed biotech investors.
Low global impact; primarily affects LRMR shareholders.
Counterpoint
Target cut could be overly cautious if BLA acceptance occurs on schedule.
Key entities
- companyLarimar Therapeutics Inc.
NASDAQ‑listed biotech developing nomlabofusp for Friedreich’s ataxia.
- analystWedbush Securities
Equity research firm that issued the target cut.
